Galectin Therapeutics’ Board Chairman Richard Uihlein Extends Existing $10 Million Unsecured Line of Credit for Two Additional Years

Galectin Therapeutics, Inc. Board Chairman Richard E. Uihlein extended by two years the $10 million line of credit that he has provided to the Company. Now, under the line of credit, the Company may borrow at the applicable federal rate published by the Internal Revenue Service (currently 2.7 percent) and obtain advances through December 31, 2021, with repayment due December 31, 2022. To date, the Company has not sought any advances under this line of credit.